Latest Merck Stories
Bernstein Liebhard LLP continues to investigate Fosamax lawsuits on behalf of individuals who suffered atypical femur fractures allegedly due to their use of Fosamax. New York, NY (PRWEB) December 01, 2012 As Fosamax lawsuits continue to move forward, a new study has found that patients who take bisphosphonates like Fosamax may be at increased risk for upper gastrointestinal cancer, Bernstein Liebhard LLP reports. The study compared 8,636 men and women who had a recorded incident of...
WHITEHOUSE STATION, N.J., Nov. 29, 2012 /PRNewswire/ -- Every few seconds, in every corner of the globe, a mother welcomes a baby into the world. A recent U.S. online survey conducted by Harris Interactive on behalf of Merck (NYSE: MRK), known as MSD outside the United States and Canada, among 2,282 adults aged 18 and up showed that nearly every parent (93 percent) characterizes this moment as "life-changing." However, what is not often discussed is that childbirth can be a very...
NEW YORK, Nov. 28, 2012 /PRNewswire/ -- Today, fashion designer and Project Runway All Stars winner, Mondo Guerra, in collaboration with Merck, unveiled an original dress created by the designer and inspired by the HIV Community. The dress is an embodiment of the Community's courage and commitment, and was designed to help inspire people living with HIV to have an open dialogue with their doctor - a key component of the I Design campaign that Mondo and Merck have been bringing to...
NEW YORK, Nov. 21, 2012 /PRNewswire/ -- As in the previous quarter, proton-pump inhibitors, antipsychotics and statins remain in the top-selling therapeutic categories. Merck's asthma and allergy preventive Singulair predictably drops out of the top five drugs due to Q3 patent loss. Top Five Drugs by Sales, Q3 2012 Drug Name Sales ($000) % Change (previous quarter) --- ------- Nexium...
VANCOUVER, British Columbia, Nov. 19, 2012 /PRNewswire/ -- Pennystocksinsiders.com (PSI) has issued insider trading reports and equity research for the following companies: Weatherford (NYSE:WFT), Merck (NYSE:MRK), Vale SA (NYSE:VALE), Coca-Cola (NYSE:KO), Altria Group (NYSE:MO), and Peabody Energy (NYSE:BTU). (Logo: http://photos.prnewswire.com/prnh/20121105/HK06856LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to your...
Merck's hepatitis C treatment receives prestigious Innovative Product Award KIRKLAND, QC, Nov. 15, 2012 /CNW/ - Merck is proud to announce that VICTRELIS(TM) (boceprevir), a first-in-class oral hepatitis C virus (HCV) protease inhibitor for the treatment of chronic hepatitis C (CHC) genotype 1 infection, received the Prix Galien Canada 2012 - Innovative Product Award. The most prestigious award in the field of Canadian pharmaceutical research and innovation,(1) this annual...
RED BANK, N.J., and WHITEHOUSE STATION, N.J., Nov. 13, 2012 /PRNewswire/ -- Vaccines play an important part in helping to maintain health and wellness for people of all ages, not just children. Yet 58 percent of American adults admit that they are not aware of the vaccines that are recommended. In fact, the US Centers for Disease Control and Prevention (CDC) has vaccination schedules for preteens, teens and adults, in addition to children. That's why HealthyWomen, a leading...
TAMPA, Fla., Nov. 12, 2012 /PRNewswire-USNewswire/ -- ISPE announced during the Plenary Session at its 2012 Annual Meeting in San Francisco, Calif. USA, that Merck's Vaccine Bulk Manufacturing Facility (VBF) Program of Projects is the Overall Winner of the 2012 Facility of the Year Awards (FOYA) program. (Logo: http://photos.prnewswire.com/prnh/20120912/DC73253LOGO) Faced with a projected production shortfall for the Varicella product franchise, Merck responded by delivering...
VANCOUVER, British Columbia, Nov. 8, 2012 /PRNewswire/ -- EarningForecast.com has issued consensus earnings forecast reports and equity research for the following companies: Wells Fargo (NYSE:WFC), General Electric (NYSE:GE), Merck (NYSE:MRK), Juniper (NYSE:JNPR), Regions Financial (NYSE:RF), and Devon Energy (NYSE:DVN). (Logo: http://photos.prnewswire.com/prnh/20121030/HK02457LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to your...
THOUSAND OAKS, Calif., Nov. 6, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that results from the LAPLACE-TIMI 57 and MENDEL Phase 2 studies evaluating AMG 145 in hypercholesterolemic patients with or without statins, respectively, showed that treatment with AMG 145 resulted in a statistically significant reduction in low-density lipoprotein (LDL) cholesterol. The two studies were presented today at the American Heart Association Scientific Sessions 2012 and...
